Treatment of Osteopenia Detected on DXA
Pharmacologic therapy is strongly recommended for osteopenia (T-score between -1.0 and -2.5) when the FRAX 10-year probability for major osteoporotic fracture is ≥20% or hip fracture is ≥3%, or when there is a history of fragility fracture 1.
Risk Stratification Determines Treatment
The decision to treat osteopenia hinges on fracture risk assessment, not just the T-score alone. Here's the algorithmic approach:
When to Treat Osteopenia:
Treat if ANY of the following:
- FRAX scores meet thresholds: Major osteoporotic fracture ≥20% OR hip fracture ≥3% at 10 years 1
- History of fragility fracture of hip or spine, even with osteopenia 1
- T-score between -2.0 and -2.5 (severe osteopenia) with additional risk factors 2
Do NOT routinely treat if:
- T-score between -1.0 and -1.5 (mild osteopenia) with low FRAX scores
- No fragility fractures
- No additional risk factors
First-Line Medication Choices:
For osteopenia meeting treatment thresholds, oral bisphosphonates (alendronate, risedronate) are appropriate initial therapy 1. These agents have proven efficacy for fracture reduction and are cost-effective 3.
Alternative agents include:
- Denosumab (if oral therapy not tolerated)
- Zoledronate (annual IV infusion)
- Ibandronate or raloxifene (spine-specific efficacy only) 1
Non-Pharmacologic Management (Universal for All Osteopenia)
Regardless of whether pharmacologic treatment is initiated:
- Calcium: 1000-1200 mg daily from diet plus supplements if needed 1
- Vitamin D: 800-1000 IU daily, targeting serum 25(OH)D >30 ng/mL 1
- Weight-bearing and resistance exercise 1
- Smoking cessation 1
- Fall risk assessment and mitigation 1
Monitoring Strategy
DXA rescreening intervals based on baseline T-score:
- Severe osteopenia (T-score -2.0 to -2.5): Repeat DXA in 1-2 years, especially in women >65 years 2
- Moderate osteopenia (T-score -1.5 to -2.0): Repeat in 2-3 years 2
- Mild osteopenia (T-score -1.0 to -1.5): Repeat in 5-7 years or longer 4, 2
Women over 65 with severe osteopenia require particularly close monitoring, as transition rates to osteoporosis reach 30.2% within 2 years and 45.9% within 2-5 years 2.
Critical Pitfalls to Avoid
Do not treat based on T-score alone without fracture risk assessment—this leads to both overtreatment of low-risk patients and undertreatment of high-risk patients with osteopenia 1.
Do not ignore fragility fractures: Any patient with osteopenia and a history of hip or spine fragility fracture requires pharmacologic therapy, as this automatically places them in the treatment category 1.
Female sex and hyperthyroidism are significant risk factors that should lower your threshold for treatment 5.
The evidence strongly supports a risk-stratified approach rather than treating all osteopenia uniformly. The 2020 AACE/ACE guidelines provide the most comprehensive framework, emphasizing that FRAX-based thresholds combined with clinical judgment determine when osteopenia warrants pharmacologic intervention 1.